FindTrial
Sign In

rhGM-CSF

DRUG8 trials

Sponsors

University of Wisconsin, Madison, Wei LUO, Shanghai Pulmonary Hospital, Shanghai, China, The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Wuhan University

Conditions

Carcinoma, Non-Small-Cell LungColon CancerLung Cancer MetastaticMelanoma (Skin)Nasopharyngeal CancersProstate CancerPulmonary Alveolar Proteinosis

Phase 1

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
NCT04072900
Xiangya Hospital of Central South UniversityMelanoma (Skin)
Start: 2020-04-21End: 2022-09-01Target: 30Updated: 2020-04-28

Phase 2

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
CompletedNCT01341652
University of Wisconsin, MadisonProstate Cancer
Start: 2011-05-23End: 2020-06-30Updated: 2021-01-20
Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis
NCT01806272
Wei LUONasopharyngeal Cancers
Start: 2013-03-31End: 2014-08-31Target: 160Updated: 2013-03-29
Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.
NCT01983657
Shanghai Pulmonary Hospital, Shanghai, ChinaPulmonary Alveolar Proteinosis
Start: 2012-01-31End: 2014-10-31Target: 40Updated: 2013-11-18
RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer
NCT02466906
The Affiliated Hospital of the Chinese Academy of Military Medical SciencesColon Cancer
Start: 2015-06-30End: 2020-07-31Target: 60Updated: 2016-01-20
A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
WithdrawnNCT02623595
Wuhan UniversityCarcinoma, Non-Small-Cell Lung
Start: 2016-05-31End: 2019-11-30Updated: 2018-10-15
Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer
CompletedNCT03113851
Peking University Cancer Hospital & InstituteLung Cancer Metastatic
Start: 2017-08-14End: 2018-10-14Updated: 2023-06-13

Unknown Phase

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients
NCT03489616
Shandong Cancer Hospital and InstituteCarcinoma, Non-Small-Cell Lung
Start: 2018-01-15End: 2019-12-31Target: 45Updated: 2018-04-05

Related Papers

Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer
Human Vaccines & Immunotherapeutics2024-08-295 citations
Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis.
2020-01-0222 citations
Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer.
Journal of Clinical Oncology2019-05-204 citations
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
Journal for ImmunoTherapy of Cancer2018-03-1359 citations
Abstract 3945: Antigen-specific immunity and regulation as predictive biomarkers for anti-tumor vaccination
Cancer Research2016-07-15
Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) versus GM-CSF adjuvant in patients with biochemically recurrent prostate cancer.
Journal of Clinical Oncology2016-05-201 citations
Abstract B147: Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with recurrent prostate cancer (NCT01341652)
Cancer Immunology Research2016-01-012 citations
Abstract CN04-03: DNA vaccines as treatment for prostate cancer - understanding mechanisms of resistance
Molecular Cancer Therapeutics2015-12-01